Melanoma drug

Continuing research on a promising melanoma drug seems to confirm early findings of its success.

Patients diagnosed with an advanced form of melanoma that has spread typically survive about 9 months.

But patients treated with Zelboraf survived an average of nearly 16 months.

Zelboraf works by blocking a mutation that’s found in about half of patients with advanced melanoma.

About half of those patients saw their tumours shrink by a third.